Trials / Recruiting
RecruitingNCT04356469
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Non-Malignant Hematological Disorders in Children
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- Sponsor
- Johns Hopkins All Children's Hospital · Academic / Other
- Sex
- All
- Age
- 0 Years – 21 Years
- Healthy volunteers
- Not accepted
Summary
This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition. This study will use stem cells obtained via peripheral blood or bone marrow from parent or other half-matched family member donor. These will be processed through a special device called CliniMACS, which is considered investigational.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Haploidentical Hematopoietic Cell Transplantation | TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation |
Timeline
- Start date
- 2020-07-22
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2020-04-22
- Last updated
- 2025-06-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04356469. Inclusion in this directory is not an endorsement.